Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of nanoparticle
albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine as first-line treatment in Chinese
patients with advanced pancreatic ductal adenocarcinoma.